Advertisement
Screener

LENSAR, INC. (LNSR) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

2.7 / 5 stars · 24/44 Roast Me

LENSAR, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

LENSAR, INC. (LNSR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 61.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-03-31

  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-09-30 was 61.00%, a 12.86% decline year-over-year.
  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-09-30 was 70.00%.
  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2021-03-31 was 73.00%.
  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 61.00%, a 12.86% decline from fiscal 2023.
  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 70.00%.
  • LENSAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 73.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month
2024-12-3161.00%
10-K · filed 2026-03-31
2024-09-3061.00%
10-Q · filed 2025-11-06
61.00%
10-Q · filed 2025-11-06
2024-06-3059.00%
10-Q · filed 2025-08-07
2023-12-3170.00%
10-K · filed 2025-02-27
2023-09-3070.00%
10-Q · filed 2024-11-07
70.00%
10-Q · filed 2024-11-07
2021-12-3173.00%
10-K · filed 2023-03-16
2021-09-3073.00%
10-Q · filed 2022-11-09
2021-06-3073.00%
10-Q · filed 2022-08-08
2021-03-3173.00%
10-Q · filed 2022-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
SkinHealth Systems Inc. (SKIN)United States$0.086B-3.17
Microbot Medical Inc. (MBOT)$0.089B-7.97
Pulmonx Corp (LUNG)United States$0.082B-1.16
RenovoRx, Inc. (RNXT)United States$0.076B-3.62
FRACTYL HEALTH, INC. (GUTS)United States$0.075B-1.18
CVRx, Inc. (CVRX)United States$0.067B-2.62
DarioHealth Corp. (DRIO)$0.066B-1.39
TELA Bio, Inc. (TELA)United States$0.057B-0.82
Apyx Medical Corp (APYX)United States$0.120B-21.85
Xtant Medical Holdings, Inc. (XTNT)United States$0.053B